Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Sil3.8

Sildenafil (Viagra) – Forschung

Überwiegend Mechanismus / Beobachtung

7 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu Sildenafil (Viagra) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus gemischt-qualitativen Meta-Analysen und randomisierten Studien, veröffentlicht 1998–2025.

Basierend auf 7 Studien · 1 Meta-Analyse · 2 RCTs

Konfidenz

Mittlere Konfidenz

Nach Outcome

Erectile functionRobuste RCT- und metaanalytische Evidenz für eine klinisch bedeutsame Verbesserung der erektilen Funktion gegenüber Placebo · ~30-60 Minuten (bei Bedarf)
Überwiegend Mechanismus / Beobachtung4 Studien
Cardiovascular & vascular
Überwiegend Mechanismus / Beobachtung4 Studien
Dementia risk (associational)
Zu wenige bewertete Studien2 Studien
Mortality (associational)
Zu wenige bewertete Studien1 Studie
Safety profile
Zu wenige bewertete Studien1 Studie

Aktives Forschungsgebiet

4 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2006

199820112025

1Systematische Übersicht2025

However, there are limitations to the evidence that should be considered.

· Unknown Journal (2025)

What did we find? • We identified 3 relevant clinical studies.
What does this mean? • Initial combination therapy with 2 oral medications, an ERA and a PDE5 inhibitor, may provide better treatment outcomes in patients with PAH compared to monotherapy.
However, there are limitations to the evidence that should be considered.

2RCT1998

Oral sildenafil is an effective, well-tolerated treatment for men with erectile dysfunction.

Goldstein, Lue, Padma-Nathan, Rosen, Steers, Wicker · The New England Journal of Medicine (1998)

Two sequential double-blind randomized trials of on-demand oral sildenafil in men with erectile dysfunction
Dose-dependent improvement in erections and successful intercourse versus placebo
Common adverse effects were headache, flushing, dyspepsia, and transient visual disturbance

Quelle ansehen

3RCT2005

Sildenafil improved exercise capacity, hemodynamics, and WHO functional class in pulmonary arterial hypertension.

Galiè, Ghofrani, Torbicki, Barst, Rubin, Badesch · The New England Journal of Medicine (2005)

SUPER-1: randomized, double-blind, placebo-controlled trial in 278 patients with PAH
Sildenafil improved 6-minute walk distance, hemodynamics, and functional class across doses
Basis for FDA approval of sildenafil (Revatio) for pulmonary arterial hypertension

Quelle ansehen

4Meta-Analyse2006

All PDE5 inhibitors meaningfully improved erectile function on the IIEF versus placebo, with sildenafil among the most effective.

Berner, Kriston, Harms · International Journal of Impotence Research (2006)

Comparative meta-analysis pooling fixed-dose RCTs of sildenafil, tadalafil, and vardenafil
All agents produced clinically meaningful IIEF improvement versus placebo
Sildenafil at maximum dose was among the most effective for erectile function

Quelle ansehen

5Kohorte2021

Among men with prior MI or revascularization, PDE5-inhibitor use was associated with lower long-term mortality than alprostadil.

Andersson, Landucci, Lagerros, Grotta, Bonamy, Krane · Journal of the American College of Cardiology (2021)

Swedish nationwide cohort of men with stable coronary artery disease treated for erectile dysfunction
PDE5-inhibitor use associated with lower all-cause and cardiovascular mortality versus alprostadil
Association was dose-dependent and stronger in younger men

Quelle ansehen

6Beobachtungsstudie2021

Sildenafil use was associated with a significantly reduced incidence of Alzheimer's disease in insurance-claims analyses.

Fang, Zhang, Zhou, Chiang, Tan, Hou, Cheng · Nature Aging (2021)

Network-medicine prioritization combined with insurance-claims pharmacoepidemiology (~7.2 million people)
Sildenafil use associated with markedly lower Alzheimer's incidence versus comparators
Mechanistic plus epidemiological strand of the dementia hypothesis

Quelle ansehen

7Beobachtungsstudie2023

A big-data analysis associated sildenafil use with a reduced risk of Alzheimer's disease.

Huo, Finkelstein · Studies in Health Technology and Informatics (2023)

Large real-world database study linking sildenafil use to lower Alzheimer's incidence
Supports a vascular/neuroprotective hypothesis for the class
Adds independent real-world replication to the Alzheimer's association

Quelle ansehen

In der Forschungsbibliothek ansehen

Sildenafil (Viagra) – Forschung

Überwiegend Mechanismus / Beobachtung

Dual Therapy for Initial Treatment of Adult Patients With Pulmonary Arterial Hypertension: Health Technologies

Oral sildenafil in the treatment of erectile dysfunction.

Sildenafil citrate therapy for pulmonary arterial hypertension.

Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.

Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease.

Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease.

Using Big Data to Uncover Association Between Sildenafil Use and Reduced Risk of Alzheimer's Disease.